Brokerages Expect M.D.C. Holdings, Inc. (MDC) to Announce $0.53 Earnings Per Share

Wall Street analysts expect that M.D.C. Holdings, Inc. (NYSE:MDC) will announce $0.53 earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for M.D.C.’s earnings, with the highest EPS estimate coming in at $0.58 and the lowest estimate coming in at $0.47. M.D.C. posted earnings of $0.40 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 32.5%. The firm is scheduled to report its next quarterly earnings report on Tuesday, May 8th.

According to Zacks, analysts expect that M.D.C. will report full-year earnings of $2.91 per share for the current financial year, with EPS estimates ranging from $2.50 to $3.10. For the next fiscal year, analysts expect that the company will post earnings of $3.41 per share, with EPS estimates ranging from $3.24 to $3.54. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover M.D.C..

M.D.C. (NYSE:MDC) last released its earnings results on Thursday, February 1st. The construction company reported $0.43 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.68 by ($0.25). M.D.C. had a net margin of 5.50% and a return on equity of 11.00%. The company had revenue of $704.26 million during the quarter, compared to the consensus estimate of $722.48 million. During the same quarter in the previous year, the business posted $0.78 EPS. The firm’s quarterly revenue was down 1.7% on a year-over-year basis.

MDC has been the subject of a number of analyst reports. UBS Group initiated coverage on shares of M.D.C. in a research note on Wednesday, October 25th. They set a “sell” rating and a $34.00 price target for the company. Zacks Investment Research upgraded shares of M.D.C. from a “hold” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research note on Thursday, February 1st. Citigroup cut their price target on shares of M.D.C. from $37.00 to $34.00 and set a “neutral” rating for the company in a research note on Friday, November 3rd. Bank of America raised their price target on shares of M.D.C. from $31.00 to $34.00 and gave the stock an “underperform” rating in a research note on Friday, February 2nd. Finally, ValuEngine cut shares of M.D.C. from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 2nd. Three research analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. M.D.C. presently has a consensus rating of “Hold” and an average target price of $33.50.

Shares of M.D.C. (NYSE MDC) opened at $29.61 on Tuesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 10.01 and a quick ratio of 3.34. M.D.C. has a one year low of $27.96 and a one year high of $37.45. The firm has a market cap of $1,660.00, a PE ratio of 11.94, a P/E/G ratio of 0.64 and a beta of 1.36.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 21st. Shareholders of record on Wednesday, February 7th will be paid a dividend of $0.30 per share. This is a boost from M.D.C.’s previous quarterly dividend of $0.25. The ex-dividend date is Tuesday, February 6th. This represents a $1.20 dividend on an annualized basis and a yield of 4.05%. M.D.C.’s dividend payout ratio (DPR) is currently 48.39%.

In other news, Director David Siegel sold 2,500 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $31.83, for a total transaction of $79,575.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Herbert T. Buchwald sold 28,350 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $31.52, for a total transaction of $893,592.00. The disclosure for this sale can be found here. Company insiders own 25.30% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Amalgamated Bank acquired a new stake in shares of M.D.C. during the second quarter worth approximately $202,000. Parsec Financial Management Inc. acquired a new stake in shares of M.D.C. during the fourth quarter worth approximately $203,000. Sawgrass Asset Management LLC acquired a new stake in shares of M.D.C. during the third quarter worth approximately $262,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of M.D.C. during the fourth quarter worth approximately $260,000. Finally, Parametrica Management Ltd acquired a new stake in shares of M.D.C. during the third quarter worth approximately $285,000. 73.84% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/02/13/brokerages-expect-m-d-c-holdings-inc-mdc-to-announce-0-53-earnings-per-share.html.

M.D.C. Company Profile

M.DC Holdings, Inc is engaged in two primary operations, including homebuilding and financial services. The Company’s segments include West, including segments located in Arizona, California, Nevada and Washington; Mountain, including segments located in Colorado and Utah; East, including segments located in Virginia, Florida and Maryland, which includes Pennsylvania and New Jersey; mortgage operations, including HomeAmerican Mortgage Corporation, and Other, which includes Allegiant Insurance Company, Inc, StarAmerican Insurance Ltd., American Home Insurance Agency, Inc and American Home Title and Escrow Company.

Get a free copy of the Zacks research report on M.D.C. (MDC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for M.D.C. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for M.D.C. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply